Regulation of Th1/Th2 Balance and Gut Microbiota by Shufeng Xingbi Therapy in Allergic Rhinitis

Study Background and Research Question

Allergic rhinitis (AR) is a prevalent non-infectious, IgE-mediated chronic inflammatory disease of the nasal mucosa, characterized by sneezing, watery discharge, nasal itching, and congestion. The global prevalence exceeds 10% and continues to rise, imposing substantial health and economic burdens (source: reference paper). Current therapies, such as corticosteroids and antihistamines, offer symptomatic relief but are often associated with adverse effects—particularly in pediatric populations. Increasing evidence connects AR pathogenesis to Th1/Th2 immune imbalance and dysbiosis of the intestinal microbiota, implicating the gut-lung axis in allergic airway diseases (source: reference paper). Traditional Chinese Medicine (TCM) approaches, including Shufeng Xingbi Therapy (SFXBT), have shown clinical promise in treating AR, but the underlying mechanisms—especially those bridging immunity and the microbiome—remain insufficiently characterized. This study addresses the question: Can SFXBT restore Th1/Th2 equilibrium and beneficially modulate the intestinal flora in AR?

Key Innovation from the Reference Study

The principal innovation lies in the integrative analysis of immune and microbiota parameters following SFXBT intervention in a validated rat model of AR. Unlike previous studies that focused on either immunological or microbial endpoints, this work directly measures both systemic (serum IgE, IL-4, short-chain fatty acids) and tissue-level (nasal mucosal mRNA/protein expression) markers, alongside comprehensive 16S rDNA sequencing of colonic contents. This dual-layered approach elucidates the interplay between immune regulation and microbiome composition, providing mechanistic insight into how SFXBT exerts its anti-inflammatory effects (source: reference paper).

Methods and Experimental Design Insights

The study employed a robust, multi-arm experimental design:

• 32 male Sprague-Dawley rats were randomized into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT.
• AR was induced via ovalbumin (OVA) sensitization and challenge, a well-established model for allergic airway inflammation.
• Interventions included oral administration of Shufeng Xingbi recipe and topical Xingbi gel nasal drops.
• Behavioral scoring quantified AR symptoms, while histopathology (H&E staining) assessed nasal mucosal inflammation.
• 16S rDNA sequencing characterized the gut microbiota.
• Biochemical assays (ELISA) measured serum IgE, IL-4, and short-chain fatty acids (SCFAs).
• RT-qPCR and Western blotting quantified mRNA and protein levels of immune-regulatory factors (STAT5, STAT6, GATA3, IL-4) in nasal tissue.

This comprehensive methodology enabled the evaluation of both primary disease features (nasal inflammation) and secondary axes (immunity-microbiome interactions).

Protocol Parameters

• animal model | 6-week-old male SD rats, 200–250 g | AR/microbiota studies | Standardization ensures reproducibility in immunological and microbiome endpoints | reference paper
• OVA induction | 1 mg ovalbumin + aluminum adjuvant | AR modeling | Recapitulates human-like Th2-driven airway inflammation | reference paper
• 16S rDNA sequencing | colon content samples | Microbiota profiling | High-resolution taxonomic analysis of gut flora changes | reference paper
• Serum IgE, IL-4, SCFAs | ELISA | Immune/metabolic status | Quantitative assessment of allergic and metabolic mediators | reference paper
• Gene/protein expression | RT-qPCR, Western blot | Nasal mucosa | Molecular markers of Th1/Th2 responses | reference paper

Core Findings and Why They Matter

The study reports several convergent lines of evidence supporting the efficacy of SFXBT in AR:

• Reduction in AR Symptoms: Both antibiotic + SFXBT and acetic acid + SFXBT groups exhibited significantly lower AR behavioral scores compared to OVA-only rats (P < 0.01), paralleled by improved nasal mucosal histology (source: reference paper).
• Immune Modulation: SFXBT treatment led to significant decreases in serum IgE and IL-4 levels (P < 0.05), as well as downregulation of STAT5, STAT6, and GATA3 at both transcript and protein levels in nasal tissue (P < 0.05). These markers are central to Th2 polarization and allergic inflammation, indicating a shift toward Th1/Th2 balance (source: reference paper).
• Microbiome Shifts: At the phylum level, fecal Firmicutes increased and Bacteroidetes decreased significantly after SFXBT intervention. At the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were enriched. These changes correlated with higher SCFA levels, metabolites known to regulate mucosal immunity and inflammation (source: reference paper).

Collectively, the data support a model in which SFXBT ameliorates AR through concerted immune and microbial modulation.

Comparison with Existing Internal Articles

Recent internal resources explore the intersection of antibiotics, microbiome modulation, and immune regulation in translational models:

• "Vancomycin as a Systems Biology Probe" discusses Vancomycin’s use in dissecting bacterial cell wall synthesis and its impact on the microbiome and immune responses in research models. While SFXBT in the current study is not an antibiotic, the referenced approaches to modulating microbiota and immunity are conceptually aligned.
• "Vancomycin: Glycopeptide Antibiotic for MRSA & Microbiome..." highlights Vancomycin’s role as a peptidoglycan precursor-binding agent in MRSA and microbiome studies, which can be leveraged in experimental designs examining antibiotic-induced dysbiosis—paralleling the antibiotic + SFXBT group in the reference study.
• Both internal articles reinforce the value of precise modulation—whether by antibiotics like Vancomycin or TCM-based interventions like SFXBT—for unraveling the immune-microbiome axis.

Limitations and Transferability

Several caveats temper the direct translation of these findings:

• The study is based on a rat model, which, while informative, may not fully recapitulate human AR or the complexity of the human microbiome (source: reference paper).
• The sample size (n=32) is appropriate for a preclinical investigation but may limit statistical power for rare outcomes.
• Mechanistic insights are suggestive rather than definitive; causal relationships between specific microbial taxa, SCFA production, and Th1/Th2 balance warrant further validation in gnotobiotic or knockout models.
• Clinical applicability of SFXBT remains to be established in well-powered human trials.

Despite these limitations, the study provides a robust framework for future research at the intersection of immunology and microbiome science.

Research Support Resources

Researchers seeking to model microbiome-immune interactions or to induce controlled dysbiosis for AR and related studies can utilize high-purity glycopeptide antibiotics such as Vancomycin (SKU C6417, APExBIO). Vancomycin’s well-characterized mechanism—binding to D-Ala-D-Ala termini of peptidoglycan precursors—makes it a preferred antibacterial agent for MRSA research, Clostridium difficile infection research, and for perturbing gut microbiota in experimental workflows (workflow_recommendation). For protocols requiring precise bacterial cell wall synthesis inhibition and reproducible microbiome modulation, Vancomycin’s solubility profile in DMSO and validated purity support rigorous study design. See APExBIO for detailed specifications and workflow guidance.